Peloton Interactive Inc is exploring apps for Amazon.com Inc’s Fire TV and Apple Inc’s Watch, Bloomberg reported on Wednesday, citing people familiar with the matter.
Cisco Systems Inc on Wednesday forecast second-quarter revenue and profit below estimates as the network gear maker struggles to shift to a software-focused company from its business of selling routers and switches, sending shares down 4%.
The Dow Jones Industrial Average and the S&P 500 posted record closing highs on Wednesday helped by a big jump in Walt Disney shares, but the Nasdaq fell as stocks were kept in check by fresh uncertainty over U.S.-China trade relations.
Technology conglomerate Cisco is plunging in after hours trade, following the release of its first-quarter results. Yahoo Finance’s Emily McCormick joins The Final Round to break down the numbers. …read more […]
When I decided to write about EnLink Midstream (NYSE: ENLC) and its 20% yield, I remarked sarcastically to our Director of Research, “I’m sure it will be a safe yield.”
Twenty percent yields almost never are.
I won’t go so far as to say that EnLink’s yield is safe – it’s not. But it does stand a real chance of receiving an upgrade next year.
EnLink has raised the distribution 19 times since 2011, though often just by a fraction of a penny. Still, the distribution is 3 1/2 times higher than it was eight years ago.
That being said, EnLink lowered the distribution …read more […]
Chicago’s mayor on Wednesday rejected an alternative proposal by Uber Technologies Inc to tax ride-hailing services, accusing the company of trying to resist any type of regulation by stirring up racial tensions.
When a private company files to go public, it can be a great opportunity for investors. People get excited about IPOs because it’s the ground floor for what that company is capable of. Even a multi-billion-dollar company has room to grow when it enters the public markets. As soon as it files an S-1 prospectus, people start putting money aside to invest in IPO stocks. For new investors or those who haven’t ever invested in a new company, it’s a good time to learn how to buy IPO stock.
The good news is, buying stock at a company’s initial public offering …read more […]
I have two questions to introduce in today’s Trade of the Day…
First, wasn’t “cutting the cord” supposed to save you money?
Yes…
And second, what’s worse than seeing an endless spinning wheel when trying to get your technology to work?
Nothing…
With both of those questions in mind, let’s look at the situation facing Walt Disney (NYSE: DIS) right now.
Yesterday, Disney launched its new streaming service called Disney Plus.
Add this new streaming service to the current list that’s available to you on the market right now – and here’s what you’ve got:
HBO: $14.99 per month
HBO Max: $14.99 per month
Amazon Prime Video: $8.99 per month
Netflix: …read more […]
Johnson & Johnson’s Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec’s public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows.
Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes. The drug, empagliflozin, was approved in 2014 in doses of 10 mg and 20 mg to help lower blood sugar levels in patients with type 2 diabetes and is marketed as Jardiance. …read more […]
Student loan borrowers from mostly black neighborhoods are almost twice as likely to default on their debt as borrowers from neighborhoods that are mostly white, according to research released Wednesday by the Federal Reserve Bank of New York.
TORONTO/MONTREAL, Nov 13 (Reuters) – Johnson & Johnson’s Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec’s public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. The plan’s administrator stopped covering Remicade, J&J unit Janssen’s version of the drug infliximab, for some new patients in February 2017, in favor of cheap near-copies called biosimilars, mainly Pfizer Inc’s version of infliximab, called Inflectra. In January, a Quebec court ordered it to resume coverage. …read more […]
New York Stock Exchange affiliate NYSE Chicago has lowered its transaction fees and eliminated rebate payments following the exchange’s transition to a new technology platform, according to a regulatory filing. The move puts NYSE Chicago’s pricing structure more in line with that of a contentious plan by the U.S. Securities and Exchange Commission called the transaction fee pilot. The NYSE is suing the regulator to prevent that from taking place. …read more […]
Nike Direct President Heidi O’Neil joined Yahoo Finance’s YFi AM to talk about the swoosh brand’s continued push into digital and why it ended its pilot with Amazon. …read more […]
Global equity markets and government bond yields fell on Wednesday as sentiment soured that a U.S.-China trade deal can be reached soon and on fears intensifying unrest in Hong Kong may lead to a Chinese crackdown.
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
